Most eyes, however, were affected at presentation: 40.3% had a VA of ≤20/50, 24.2% had a VA of ≤20/200, and 60.2% had at least one ocular complication. The incidence of VA loss to the ≤20/50 threshold was 0.18 per eye-year (EY) and 0.09 per EY to the ≤20/200 threshold. The investigators calculated the incidence of developing at least one new ocular complication over follow-up as 0.15/EY.
Patients who had uveitis but whose eyes did not have complications at presentation had a 0.04/EY rate of developing at least one ocular complication during follow-up.
Increasing anterior chamber cell grade was associated with a dose-dependent increase in visual loss. In particular, active uveitis was associated with loss of VA for anterior chamber cell levels of 1+ or higher. Although the reduction in VA may be reversible in some cases, the authors assumed, when calculating risk of vision loss from uveitis, that the eyes never recover VA.